Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com
  • 5.0 (1)
  • HEALTH & FITNESS

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. Can Eye Blood Vessel Changes Warn of Future Glaucoma Damage Before Vision Tests Turn Abnormal?

    12H AGO

    Can Eye Blood Vessel Changes Warn of Future Glaucoma Damage Before Vision Tests Turn Abnormal?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/can-eye-blood-vessel-changes-warn-of-future-glaucoma-damage-before-vision-tests-turn-abnormal Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Glaucoma suspects are people who have signs or risk factors for glaucoma but still have normal vision tests. For example, a person might have high eye pressure or a suspicious-looking optic nerve at the back of the eye. Doctors say a glaucoma suspect is someone “with one or more clinical features or risk factors” of future optic nerve damage (). Being a suspect means careful monitoring, not that vision is lost yet.Glaucoma is often called a “silent thief of sight.” It quietly damages the optic nerve before any vision loss shows up. Structural damage means actual changes in the optic nerve or its fibers. Vision loss on a visual field test means those changes have started affecting what you see. In most cases, scans of the eye (like OCT scans) can see nerve thinning before a patient notices any vision change. Experts note that glaucoma damage usually remains asymptomatic until a lot of damage is done (). In fact, many studies find that structural changes in the nerve can be seen years before a visual field test shows problems (). In simple terms, imaging scans can detect early nerve damage before it hurts your eyesight. Microvascular dropout and beta-zone parapapillary atrophy are scan findings eye doctors watch. Microvascular dropout refers to areas where tiny blood vessels around the optic nerve are missing. On special scans called OCT-angiograms (OCTA), these spots look like patches with no blood flow. For instance, researchers describe it as a “complete focal loss of microvasculature” in the tissue around the nerve (). In plain language, imagine there’s a map of blood vessels feeding the nerve, and small sections of that map suddenly have big gaps. Those gaps are microvascular dropout.Beta-zone parapapillary atrophy (beta-zone PPA) is an area of thinning just next to the optic nerve head. The retina there has lost some of its pigment and cells. In doctors’ terms, zone-β PPA is where you can actually see the white sclera (the eye’s “white”) and choroidal blood vessels because the retinal layers are gone (). Put simply, it’s like a bare patch around the nerve where normal retina tissue has worn away. (There is also an “alpha zone” farther out that has irregular pigment, but beta-zone is the inner ring closest to the nerve.) In glaucoma patients, a larger beta-zone often means more nerve damage. The March 17, 2026 study focused on glaucoma suspects and early (preperimetric) glaucoma – people who show early signs on scans but still have normal visual fields. It found that two scan changes may predict future optic nerve damage even before vision tests change. Patients whose scans showed microvascular dropout or an enlarging beta-zone atrophy tended to have optic nerve thinning on later exams. In other words, these eyes were more likely to show structural progression on follow-up. This matches past research: for example, one study found that larger beta-zone PPA at baseline led to faster nerve fiber loss over time (). In the glaucoma-suspect study, eyes with either microvessel dropout or growing beta-zone atrophy had more nerve fiber thinning later on, suggesting these could be early warning markers. Because structural changes often come before symptoms, these findings matter. If Support the show

    8 min
  2. Does Angle-Closure Risk Build Up Earlier in Life Than People Think?

    1D AGO

    Does Angle-Closure Risk Build Up Earlier in Life Than People Think?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/does-angle-closure-risk-build-up-earlier-in-life-than-people-think Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: What Is Angle-Closure Glaucoma? Angle-closure glaucoma is a type of glaucoma where the front part of the eye (the drainage angle) becomes blocked. In a healthy eye, a clear fluid called aqueous humor flows through a space called the anterior chamber (behind the cornea and in front of the iris) and drains out through tiny openings. In angle-closure glaucoma, the colored part of the eye (the iris) bulges or moves forward and blocks the drainage angle, so the fluid cannot leave the eye. When fluid builds up, it raises the pressure inside the eye. If this pressure rises suddenly, it can cause severe eye pain, blurred vision, halos around lights, nausea, and even rapidly lead to vision loss. In simple terms, angle-closure glaucoma is like a sink whose drain gets suddenly blocked, causing the “water” (eye fluid) to back up. This needs prompt medical attention . The Anterior Chamber and What “Shallow” Means The anterior chamber is the front part of your eye. It’s the space filled with clear fluid between the cornea (the clear “window” at the very front of the eye) and the iris (the colored ring around the pupil). You can think of it as a small bowl of fluid at the front of the eye (). The depth of this chamber (how deep or shallow it is) is important. A deep chamber means there is plenty of space in front of the iris; a shallow chamber means the iris is closer to the cornea. When the anterior chamber is shallow, the drainage angle at the edge of the chamber can be very narrow. A narrow or shallow chamber can limit fluid flow out of the eye, and research links shallower anterior chambers with a higher risk of glaucoma (). In other words, imagine a shallow bowl versus a deep bowl – in the shallow bowl there is less room for fluid to circulate, making blockage more likely. New Research: How Eye Shape Changes with Age A study published in March 2026 looked at how the anterior chamber changes as people get older. Researchers in Japan measured the anterior chamber depth (ACD) in a large group of adults of different ages. They found that the chamber tends to become shallower (smaller) more quickly in younger adults than expected, and then the change slows down in middle age. In plain language, most of the change in eye shape happens earlier in adulthood rather than steadily getting worse in older age. In fact, in one Japanese health-screening study of over 3,000 people, age was a strong predictor of ACD after accounting for other factors (). This means that by the time many people reach their 40s or 50s, their eyes may have already reached a stable shape. In effect, people who will have narrow angles tend to already have them when they are younger. (By contrast, other studies have shown that overall, ACD does decrease with age (), but the new finding is that much of that decrease may occur earlier than doctors used to think.) In practical terms, it suggests that the risk factors for angle closure may be set up earlier in life. However, it’s important to remember that even if your eyes are a bit narrow when you’re younger, that doesn’t guarantee problems later – it just highlights that any risk might start early. This research is a piece of the puzzle, and it shows doctors how eye anatomy tends to change over time. Why This Matters for Ea Support the show

    11 min
  3. Can Exercise, Better Sleep, and Stress Reduction Help in Glaucoma? What a New March 2026 Study Suggests

    2D AGO

    Can Exercise, Better Sleep, and Stress Reduction Help in Glaucoma? What a New March 2026 Study Suggests

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/can-exercise-better-sleep-and-stress-reduction-help-in-glaucoma-what-a-new-march-2026-study-suggests Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Can Exercise, Better Sleep, and Stress Reduction Help in Glaucoma? What a New March 2026 Study SuggestsGlaucoma is an eye disease where high pressure hurts the optic nerve, causing vision loss. A new report (March 2026) suggests that healthy lifestyle habits might support glaucoma care. It says that exercise, meditation, good sleep, not smoking, and a healthy diet may help keep eyes healthier. However, these are extra supports – they are not a cure and do not replace your doctor’s treatment. Doctors still agree that the only proven way to slow glaucoma is to lower eye pressure with medicine, laser, or surgery () (). Researchers are interested in lifestyle factors because glaucoma involves more than just eye pressure. Things like poor blood flow, stress, or low energy in nerve cells also play a role. Exercise and good nutrition can improve blood flow and nerve health, while stress and smoking can do the opposite. For example, a review in Clinical & Experimental Ophthalmology notes that aerobic exercise and meditation may help protect the optic nerve and slow glaucoma progression () (). In another recent nutrition review, getting more natural nitrates (found in leafy greens) and good sleep were linked to lower glaucoma risk, while smoking and heavy drinking were linked to more eye damage () (). In short, doctors think a healthy body supports healthy eyes.Supporting vs. CuringSupporting eye health: Habits that keep your whole body strong (like exercise and good diet) also help your eyes get better blood flow and nutrients () (). This can make your eyes more resilient. Lowering risk: For people without glaucoma, healthy habits might lower the chance of getting it. For example, studies show people who eat lots of green vegetables (rich in nitrates) have a lower risk of developing glaucoma (). Slowing progression: If you already have glaucoma, these habits might slow how fast it gets worse. In one study, glaucoma patients who walked more each day had slower vision loss over five years (). Another review found that meditation and exercise were linked to slower nerve damage in glaucoma () (). Replacing treatment: Importantly, none of these habits replace your doctor’s treatment. They are added support, not alternatives. No exercise or diet has been proven to cure glaucoma. We still need medicines or surgery to control eye pressure () ().What May Help Overall Eye and Body HealthRegular exercise. Aim for about 30 minutes of moderate aerobic activity most days (brisk walking, swimming, cycling). Exercise improves blood flow and can slightly lower eye pressure () (). It’s good for your heart and eyes. Healthy diet. Eat plenty of vegetables and fruits (especially leafy greens, berries, beans) and lean proteins (fish, poultry). A Mediterranean-style diet or a daily green salad is a good goal. Leafy greens have special nitrates and nutrients linked to better eye blood flow and lower glaucoma risk () (). Avoid too much sugar or processed food. Good sleep. Try to get 7–8 hours of quality sleep every night. Keep a regular sleep schedule. Some studies suggest that poor sleep or sleeping face down can raise eye pressure, while steady breathing and rest help your whole body and Support the show

    8 min
  4. If One Person in the Family Has Glaucoma, Should Everyone Else Get Checked?

    3D AGO

    If One Person in the Family Has Glaucoma, Should Everyone Else Get Checked?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/if-one-person-in-the-family-has-glaucoma-should-everyone-else-get-checked Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Why family history matters so much in glaucoma Glaucoma is an eye condition that can quietly damage the optic nerve – the nerve that sends vision signals to the brain. Often there are no early symptoms, so people don’t notice any vision loss until late. Because of this, knowing your risk is very important. One big risk factor is family history. In fact, doctors say glaucoma often runs in families. Genetic studies suggest that more than half of glaucoma cases are due to inherited factors (). That means if someone in your close family has glaucoma, your own risk goes up. An eye-care society notes that if a parent, brother, sister, or child (called an immediate family member) has glaucoma, you are about 10 times more likely to get glaucoma yourself ().Importantly, having a family history doesn’t guarantee you will get glaucoma, and not having a family history doesn’t guarantee you won’t. It’s a risk factor, not a certainty. For example, one review found that first-degree relatives of glaucoma patients had an estimated 22% lifetime risk of glaucoma, compared to only about 2% in people without any family history (). In another screening study, about 15% of siblings of glaucoma patients had glaucoma, and 20% of parents did, while only 4% of children (often still young) were diagnosed (). These numbers show higher risk for close relatives, especially siblings and parents, but still a majority of relatives might not have it. Other factors also affect risk – for example, older age or certain ancestries can raise glaucoma risk too (). In short, family history is important because it raises your chances, but it’s one of several factors. What recent research shows about family risk A report published in March 2026 summarized many studies on this topic. That review found that a large fraction of relatives of glaucoma patients show signs of the disease. For example, one study of family members found 8.3% of relatives already had glaucoma and another 19.2% were “glaucoma suspects” (meaning they had early warning signs) (). Altogether, that’s about 27% of relatives with disease or suspected disease. In another clinic study, 13.3% of screened relatives had confirmed glaucoma (). Putting these together, the review concluded that roughly one quarter to one third of close relatives may be affected or at high risk. In practical terms, this means that if you learn a family member has glaucoma, doctors advise that other first-degree relatives – especially siblings – pay attention. The latest research underscores that checking relatives can find many cases early, because one in four or one in three is a much higher count than would be found by chance. Underlying this is the fact that glaucoma has up to 70% heritability (), meaning much of the risk is passed along family lines.Why screening family members is important Glaucoma can slowly steal sight without you noticing. Many people call it a “silent thief of sight.” Surveys estimate nearly half of people with glaucoma don’t know they have it (). The damage is permanent once it occurs, so the key is catching glaucoma early before vision is lost. Early treatment with prescription eye drops, laser or surgery can slow or stop the disease and protect vision (). For Support the show

    11 min
  5. A New Glaucoma Drug Study Is Starting: Could an Oral Cannabinoid Help Lower Eye Pressure?

    4D AGO

    A New Glaucoma Drug Study Is Starting: Could an Oral Cannabinoid Help Lower Eye Pressure?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-drug-study-is-starting-could-an-oral-cannabinoid-help-lower-eye-pressure Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: A New Glaucoma Drug Study Is Starting: Could an Oral Cannabinoid Help Lower Eye Pressure?Some patients may have seen news on March 18, 2026 about a new drug trial for glaucoma and wondered what it means. It’s about a medicine called ART27.13, an experimental oral drug aimed at lowering eye pressure in people with glaucoma or ocular hypertension. In simple terms, this is only a research study. The drug is not FDA-approved or proven to work yet. It is being tested to see if it can safely lower the pressure inside the eye. Before we dive in, let’s remember why eye pressure matters. Glaucoma is a group of eye conditions where high pressure or poor blood flow damages the optic nerve at the back of the eye. That nerve damage causes vision loss. Once vision is lost from glaucoma, it cannot be restored () (). So doctors focus on slowing the damage, not fixing it. The only proven way to slow glaucoma is by lowering the pressure in the eye (). Today this is usually done with eye drops or surgery. A new study is exploring whether ART27.13, an oral drug, can join these treatments. What Is ART27.13?ART27.13 is the code name for a new experimental drug. It is related to cannabinoids – the kinds of active compounds found in the cannabis plant – but it is specially made in a lab. It is taken by mouth (an oral tablet). The reason researchers are interested is that some cannabinoids can lower eye pressure. However, ART27.13 is not just cannabis. It is designed to work mainly outside the brain. In other words, it should not make someone feel high or have the same effects as marijuana. Scientists hope it targets only the eye and body tissues involved in pressure. No one can take ART27.13 outside a doctor’s study right now – it’s only being given to volunteers in the trial. Remember: this is early clinical research. ART27.13 is not an approved medicine yet. It is being studied to see if it is safe and if it can lower eye pressure. We do not know if it will help; that is exactly what the trial is meant to find out. Why Are Cannabinoids of Interest in Glaucoma?Cannabinoids have a long history in glaucoma research. Many people know that marijuana can lower eye pressure a bit (at least for a few hours). In fact, cannabis and related compounds have been known since the 1970s to temporarily reduce intraocular pressure (). Studies show that taking THC or synthetic cannabinoids by mouth can drop pressure by up to about 10–30%, but only for a few hours (). After that, the pressure goes back up. (One review found the maximum drop at 2–4 hours after dose, and it stopped in 3–4 hours () ().) Because of this, some researchers wondered if certain cannabinoids could help with glaucoma. Cannabinoids also have other effects that might help: they can improve blood flow to the optic nerve and may reduce inflammation. But there are problems with using ordinary cannabis. The drop in eye pressure is short-lived and would require dosing many times a day () (). Meanwhile, marijuana causes side effects like feeling “high,” tiredness, and faster heartbeat. Because of that, eye doctors do not use medical cannabis to treat glaucoma. As one eye specialist explained, most glaucoma doctors believe “marijuana is really ineffective” for tre Support the show

    14 min
  6. What Was Actually New in Glaucoma This Month? A Plain-English Guide to the Most Important March 2026 Updates

    5D AGO

    What Was Actually New in Glaucoma This Month? A Plain-English Guide to the Most Important March 2026 Updates

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/what-was-actually-new-in-glaucoma-this-month-a-plain-english-guide-to-the-most-important-march-2026-updates Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction Glaucoma is a common eye disease that slowly damages the optic nerve and can lead to permanent vision loss. It is usually painless and often unnoticed until vision is already affected. Worldwide, tens of millions of people have glaucoma, making it one of the leading causes of blindness (). Because there is no cure, treatment focuses on slowing or stopping the damage. Almost all current treatments work by lowering eye pressure and require ongoing therapy with eye drops, laser, or surgery. Unfortunately, many patients find daily eye drops hard to use correctly. As one recent review notes, drop therapy often has drawbacks like poor patient adherence (many people forget or fail to use them as prescribed) and side effects () (). This is why scientists and doctors are always looking for better ways to control pressure and protect the optic nerve.In March 2026, several new glaucoma studies and reports drew attention. Some of these findings are already hinting at practical improvements for patients, while others are early-stage research that may only pay off far in the future. This guide will explain the most important updates from the month in plain English: what might help patients soon and what still needs more research (especially distinguishing better diagnosis and monitoring tools versus true treatments or cures). We’ll also flag which headlines deserve caution. What Could Matter to Patients Now New drug-delivery implants (lens/implants for pressure control). One of the biggest practical advances is progress on “sustained-release” implants that deliver glaucoma medicine inside the eye, potentially replacing daily eye drops. For example, an FDA-approved glaucoma implant (bimatoprost intracameral implant, brand name Durysta) can already release a pressure-lowering drug for months after a single insertion (). In March there was news about a related approach: an intraocular lens (IOL) or implant that contains bimatoprost (a common glaucoma drop) and releases it slowly. Although this “BIM-IOL” device still needs more testing, it could eventually be used during cataract surgery so that one procedure also helps control glaucoma pressure without extra drops. These types of long-acting drug devices may arrive in clinics soon. They build on the success of Durysta, and experts note that such sustained-release therapies are an active development area (). Capturing slow changes in eye pressure and fields (monitoring). A recent study (the ADAGES group) looked at long-term glaucoma data and found that changes in eye pressure and vision loss don’t always happen at the same time. In simple terms, your visual field (what you can see on a vision test) often lags behind pressure changes by months or years. This is actually reassuring: it means if your pressure goes up or down a bit, your doctor may have time to notice structural changes (e.g. on scans) before you notice any vision loss. For patients, the takeaway is to trust that doctors will catch worsening disease early with regular tests, even if you feel fine. It emphasizes the monitoring side of care: keep up with check-ups and imaging. (This is mainly a research finding, but i Support the show

    12 min
  7. Why Is It So Hard to Prove a Treatment Protects the Optic Nerve in Glaucoma?

    6D AGO

    Why Is It So Hard to Prove a Treatment Protects the Optic Nerve in Glaucoma?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/why-is-it-so-hard-to-prove-a-treatment-protects-the-optic-nerve-in-glaucoma Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction When you hear hopeful news about neuroprotection for glaucoma, it’s natural to wonder what that means. In glaucoma, the goal of neuroprotection is to protect the eye’s nerve cells – the ones that carry signals from the eye to the brain – from damage. In other words, neuroprotective treatments aim to keep the optic nerve healthy and alive, not just by lowering eye pressure (the pressure inside the eye, called intraocular pressure), but by directly shielding nerve cells from injury (). As one Cochrane review explains, neuroprotection in glaucoma is any treatment intended to prevent optic nerve damage or cell death (). However, a recent analysis (March 11, 2026) highlights why proving neuroprotection in people is so challenging. The study points out that glaucoma often progresses very slowly and that the usual tests used to measure optic nerve health can be “noisy,” so it’s hard to see clear benefits over a short time. In this article we will explain what neuroprotection means in glaucoma, how it differs from the familiar approach of lowering intraocular pressure, and why this new paper (and others) say neuroprotection trials face big hurdles. We’ll also discuss why many treatments that look promising in the lab fail to become real-world therapies, what kind of evidence doctors need to be convinced a treatment truly protects nerves, and what all this means for patients hoping for more than pressure-lowering therapies.Neuroprotection in Glaucoma: What Does It Mean? Glaucoma is essentially a disease of the optic nerve, where the retinal ganglion cells (the nerve cells in the eye) gradually die off. This death of nerve cells is what causes vision loss in glaucoma (). Right now, all approved glaucoma therapies focus on lowering intraocular pressure, which is the main risk factor for nerve damage. By lowering eye pressure with drops, lasers, or surgery, we can delay glaucoma from getting worse () (). However, even when eye pressure is well controlled, some nerve damage can still happen. That’s why scientists talk about neuroprotection – treatments that go beyond pressure lowering and try to directly save or strengthen the nerve cells.For example, imagine a treatment that boosts the survival of optic nerve fibers or blocks harmful chemical processes in the nerve. If such a treatment were proven to slow down nerve damage, we would call it a neuroprotective therapy. In contrast, a pressure-lowering eye drop does not directly heal or protect the nerve; it simply eases the pressure on it. And “restoring lost vision” is an even bigger leap – that would mean regenerating or replacing the nerve cells and reconnecting them to the brain. Currently, that level of nerve regeneration is largely experimental (ideas like gene therapy or stem cells are being studied) and is not an available treatment () ().To sum up: Lowering eye pressure reduces the mechanical stress that contributes to glaucoma, slowing nerve damage is the job of neuroprotective interventions (if we had them), and restoring lost vision would require repairing or regrowing the damaged nerve, which is still far in the future.Lowering Pressure vs. Protecting Nerves vs. Restoring Vision These three goals – pressure lowering, neuroprotection, and vision re Support the show

    16 min
  8. A New Way to Read Eye Scans in Glaucoma: Can 3D Nerve Fiber Shape Improve Detection?

    MAR 18

    A New Way to Read Eye Scans in Glaucoma: Can 3D Nerve Fiber Shape Improve Detection?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/a-new-way-to-read-eye-scans-in-glaucoma-can-3d-nerve-fiber-shape-improve-detection Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: What Is the Retinal Nerve Fiber Layer (RNFL) and Why It Matters in GlaucomaYour retina at the back of the eye has many layers, including one called the retinal nerve fiber layer (RNFL). This layer is made of long fibers (the axons of retinal ganglion cells) that gather at the optic nerve and carry visual signals to the brain (). In glaucoma, a common eye disease, these nerve cells and their fibers slowly die off. This loss leads to thinning of the RNFL. Doctors rely on finding this thinning as an early sign of glaucoma damage () (). Detecting changes in the RNFL is key because by the time vision loss appears on a field test, about 25–40% of these nerve cells may already be lost () (). In other words, by catching RNFL thinning early, eye doctors hope to treat glaucoma sooner and protect vision.How Doctors Usually Look for Glaucoma on ScansTo check the RNFL, doctors commonly use optical coherence tomography (OCT), a non-invasive imaging test that takes cross-sectional “slice” pictures of the retina. OCT is like an ultrasound for the eye, but it uses light waves to give very detailed images. Most clinical OCT machines take a circular scan around where the optic nerve exits the eye and calculate the RNFL thickness at each point (). This creates a thickness map – it’s often drawn as a double-humped curve (thicker on the top and bottom, thinner on the sides in healthy eyes) (). If glaucoma is present, doctors will see areas where the RNFL is thinner than expected, meaning there are fewer nerve fibers there. In practice, the RNFL thickness measurement from one cross-sectional slice of the OCT is the standard glaucoma parameter ().However, this standard 2D thickness measure has limits. It comes from a single circular scan rather than the whole 3D volume of the scan (). Some scans can be distorted by eye movement or blood vessels, causing artifacts in 20–46% of cases (). Also, in very early glaucoma, thinning might be subtle or patchy and could be missed if one only looks at average thickness values. Researchers have noted that while RNFL thinning is strongly linked to glaucoma, doctors may need to look beyond just simple thickness to improve early detection (). The New 3D Shape-Based Analysis of the RNFLThe 2026 study introduces a new idea: instead of just measuring how thick the RNFL is at a single slice, what if we analyze the whole 3D shape of that nerve fiber layer? Think of it this way: a normal OCT produces a 3D block of data around the optic nerve. Much of that data is not fully used by standard software. The new method, called a registration-based 3D RNFL shape analysis, tries to use more of this information. In simple terms, it lines up the 3D scan images (this is the “registration” part) and looks at the detailed shape of the RNFL surface. It’s like taking a detailed mold of the nerve fiber layer and checking if there are any dents or bumps that indicate damage.Here are the key ideas in patient terms:Full-volume use: Instead of a single circular slice, the method examines every part of the RNFL volume from the OCT scan. This may reveal changes that a single cross-section misses.Shape vs thickness: It doesn’t just report a number for “thickness” at each point. It analyzes the contours and geometry Support the show

    11 min
See All (132)

About

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

Information

You Might Also Like